Lung Cancer - Non Small CellNCT07216209
The Impact of Exercise on the Tumor Microenvironment in Patients With Lung Cancer
A study testing EXERCISE TRAINING WITH OR WITHOUT MEDICATION in people with Lung Cancer - Non Small Cell, run by University of Arizona at 1 site in United States.
Trial summary
There is increased interest and knowledge about the lung cancer tumor microenvironment (TME). Investigators hypothesize that patients with better baseline physiologic health will have better post-operative outcomes and that strenuous exercise will alter the TME and genetic make-up of the tumor, improving the tumor… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Lung Cancer - Non Small Cell
- What is being tested?
- EXERCISE TRAINING WITH OR WITHOUT MEDICATION
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 48 participants
- Where
- 1 siteUnited States
- Study dates
- 13 Jan 2026to 15 Jan 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- lung cancer
- low risk for submaximal exercise testing in accordance with the risk stratification guidelines published by the American Heart Association and the American College of Sports Medicine (AHA/ACSM criteria).
Who cannot join
- younger than 18 years of age
- select a condition on the ACSM-AHA pre-exercise screening questionnaire indicating that physician approval is required prior to exercise
- body mass index of >30 kg/m2
- waist girth of >102cm for men and >88cm for women
- have chronic/debilitating arthritis
- have been bedridden in the past three months
Show all 15Show fewer
- have common illness (i.e. colds) within the past 6-weeks
- HIV
- hepatitis
- history of stroke
- major affective disorder
- autoimmune disease
- pregnancy or are breast-feeding
- history of severe anaphylactic reaction to an allergen
- present with more than one of the following CVD risk factors: family history of myocardial infarction, coronary revascularization, or sudden death before 55 years of age in father or other male first-degree relative or before 65 years of age in mother or other female first-degree relative
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of Arizona Cancer Center
Tucson, Arizona, 85719
Stephanie Worrell, MD, 520-626-7806, sworrell@arizona.edu
Melissa Landau, 5206267806, mlandau@surgery.arizona.edu
About this study
Official title: Exercise and the Lung Cancer Tumor Microenvironment
There is increased interest and knowledge about the lung cancer tumor microenvironment (TME). Investigators hypothesize that patients with better baseline physiologic health will have better post-operative outcomes and that strenuous exercise will alter the TME and genetic make-up of the tumor, improving the tumor immune response. Investigators aim to identify the peri-operative and clinical outcomes that differ based on pre-operative VO2max, HRV and resting heart rate following resection of early-stage lung cancer. The physiologic states that are individual and measurable with wearable devices include but are not limited to VO2max, heart rate variability (HRV), and average resting heart rate. Investgators hypothesize that a patient's pre-operative physiologic function with higher VO2max, HRV and lower resting heart rate will be associated with improved peri-operative and post-operative outcomes. Second, investigators will compare alterations in TME based on targeted pre-operative exercise (60-80% of their VO2 max for 75min/week x2 weeks) compared to normal activity adults following resection of early-stage lung cancer. Investigators hypothesize that strenuous exercise in the pre-operative period will impact the TME by increasing levels of cytokines.
Read the detailed description
Background
Lung cancer continues to be the most common cause of cancer related death in both men and women. Patients have variable responses to treatment, whether they receive neoadjuvant therapy or surgery alone. Many of these variations can be attributed to known patient risk factors including age, smoking status, and BMI. However, there are more complex pathophysiologic factors that affect how patients respond and recover from all insults, including cancer.
Lung cancer resides in a complex milieu known as the lung tumor microenvironment (TME). The TME includes the cellular makeup of the tumor as well as factors such as IL6, PDL1 ligand, COX2, PGE2, and other cytokines. These factors can cause the TME to change in states of inflammation, such as COPD, and impact carcinogenesis (1-3). Thus, it is reasonable to assume that other physiologic alterations can change the TME. These physiologic states may be alterable and could be used to improve the efficacy of targeted therapies.
The innate and adaptive immune cells in the lung TME harbor tumor promoting and suppressing activities, which may affect clinical outcomes. Cancer associated fibroblasts (CAF) isolated from human lung cancer tissues have been shown to secrete interleukin-6 (IL-6), which then stimulates Janus kinase 2(JAK2)-signal transducers. Through this mechanism, transcription 3 (STAT3) signaling is activated and ultimately leads to increased metastasis in vivo. CAFs modulate multiple immune pathways in the TME, as they also express PDL1 to blunt activation of T cells and cross present antigens to eliminate antigen-specific CD8+T cells via PDL2 and FASL. CAFs have been found to be indicators of poor prognosis, associated with nodal metastases and increased risk of recurrence (6).
Physical fitness and moderate intensity exercise training have been shown to improve immune responses to vaccination, reduce chronic low-grade inflammation, and improve various immune markers in several disease states including cancer, HIV, cardiovascular disease, diabetes, cognitive impairment, and obesity (4). In mouse models, exercise has been shown to decrease tumor incidence and growth by over 60% (5). Prior work by Simpson and colleagues have shown that even a single bout of aerobic exercise greatly increases NK cell and γδ T cell numbers as well as increases the proportion of total lymphocytes found in the peripheral blood. Exercise can also increase the number of cytotoxic T cells in the blood without increasing their proportion of total lymphocytes.
This study will capture the baseline physiologic state of patients with resectable lung cancer pre-operatively. The parameters captured will include but are not limited to: VO2max, heart rate variability (HRV), and average resting heart rate. Next, investigators will perform strenuous exercise on a subset of these patients and correlate this data with their TME and clinical peri-operative and post-operative outcomes. The TME will be evaluated with flow cytometry and real-time PCR after tumor resection and levels of IL1b, 4,6,11,12, TNFa, MCP1, TGFb, CD4 and 8 will be identified as well as the presence of PDL-1, EGFR mutations, ALK, ROS1, KRAS, BRAF.
In our clinical pilot data, strenuous exercise patients had important trends. Patients who self-reported strenuous exercise had better lung function, shorter time from diagnosis to surgery, more left sided tumors, shorter hospital LOS, and less prolonged air leaks. Long term outcomes are still pending regarding recurrence and overall survival.
Investigators hypothesize that patients with better baseline physiologic health will have better post-operative outcomes and that strenuous exercise will alter the TME and genetic make-up of the tumor, improving the tumor immune response to targeted therapies.
Specific Aims
Aim 1: Identify the peri-operative and clinical outcomes that differ based on pre-operative VO2max, HRV and resting heart rate following resection of early-stage lung cancer. The physiologic states that are individual and measurable with wearable devices include but are not limited to VO2max, heart rate variability (HRV), and average resting heart rate. Investigators hypothesize that a patient's pre-operative physiologic function with higher VO2max, HRV and lower resting heart rate will be associated with improved peri-operative and post-operative outcomes.
Aim 2: Compare alterations in TME based on targeted pre-operative exercise (60-80% of their VO2 max for 75min/week x2 weeks) compared to normal activity adults following resection of early-stage lung cancer. Investigators hypothesize that strenuous exercise in the pre-operative period will impact the TME by increasing levels of cytokines.
Significance
There is increased interest and knowledge about the lung cancer TME. There are data that demonstrate that alterations in the TME can occur based on inflammation. The literature also shows that increased level of CD8 and PDL1 expression are associated with better response to anti-PD-1 treatment (7). This occurs through the binding of PD-L1 to its receptors, which suppresses T-cell migration, proliferation and secretion of cytotoxic mediators and restricts tumor cell killing.. The PD-L1-PD-1 axis protects the host from overactive T-effector cells not only in cancer but also during microbial infections (8). If investigators can alter the level of cytokines and PD-LI expression with strenuous exercise, then patients: 1) may have improved operative outcomes, 2) could experience altered (improved) TME and may demonstrate improved response to targeted therapies.
Research Plan
Patients will be recruited from three busy thoracic surgery clinics, which see at least 30 lung cancer patients per month. All patients will be given a wearable device to record their physiologic data 24 hours/day for 2-3 weeks pre-operatively. This data will include VO2 max, HRV, resting heart rate and sleep score. The patients' peri-operative and post-operative outcomes will be recorded in a database and this data will then be linked to the patients' recorded physiologic data.
In addition to this baseline monitoring, all patients will be offered a lab exercise regimen. For completion of Aim 2, only three or four visits are necessary, amounting to approximately 4 hours of the patient's time. The initial visit will be for pre-exercise screening. If the patient is deemed healthy enough to participate, an exercise test to determine the ventilatory threshold of the participant will be conducted and the VO2 determined. In the subsequent visits, the patient will perform exercise for 30 minutes at 15% above the volunteer's ventilatory threshold. Ideally, the patients will be able to complete a minimum of three sessions prior to surgery. Those who are not able to participate due to interest or limitations in travel or physical limitations will serve as the control group.
Lung cancer specimens will be collected from all patients at the time of surgery. Investigators will perform flow cytometry and real-time PCR to identify levels of IL1b, 4,6,11,12, TNFa, MCP1, TGFb, CD4 and 8, and the presence of PDL-1, EGFR mutations, ALK, ROS1, KRAS, BRAF.
The next steps for this study will be to reproduce these experiments in a mouse model that has been previously performed by the collaborating lab. In this model investigators will be able to give targeted therapies, such as, PDL-1 inhibitors and measure the rate of response with and without strenuous exercise.
- Conditions
- Lung Cancer - Non Small Cell
- Being tested
- EXERCISE TRAINING WITH OR WITHOUT MEDICATION
- Keywords
- exercise, tumor microenvironment, lung cancer
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung, Motor Activity, Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EXERCISE TRAINING WITH OR WITHOUT MEDICATIONBehavioural
All patients will be offered a lab exercise regimen. For completion of Aim 2, only three or four visits are necessary, amounting to approximately 4 hours of the patient's time. The initial visit will be for pre-exercise screening. If the patient is deemed healthy enough to participate, an exercise test to determine the ventilatory threshold of the participant will be conducted and the VO2 determined. In the subsequent visits, the patient will perform exercise for 30 minutes at 15% above the volunteer's ventilatory threshold. Ideally, the patients will be able to complete a minimum of three sessions prior to surgery.
| Study group | Role | What they receive |
|---|---|---|
| Exercise arm | Experimental | All patients will be offered a lab exercise regimen. For completion of Aim 2, only three or four visits are necessary, amounting to approximately 4 hours of the patient's time. The initial visit will be for pre-exercise screening. If the patient is deemed healthy enough to participate, an exercise test to determine the ventilatory threshold of the participant will be conducted and the VO2 determined. In the subsequent visits, the patient will perform exercise for 30 minutes at 15% above the volunteer's ventilatory threshold. Ideally, the patients will be able to complete a minimum of three sessions prior to surgery. Receives: Behavioral: EXERCISE TRAINING WITH OR WITHOUT MEDICATION |
What is being measured
The primary outcome is the main question the study is designed to answer.
Tumor Microenvironment
Lung cancer specimens will be collected from all patients at the time of surgery. Investigators will perform real-time PCR to identify levels of PDL-1
Measured: Baseline, Perioperative, up to 24 months
Secondary outcomes (1)
Recurrence and Survival
Patients will be compared for evidence of recurrence and followed for long-term survival
Measured: Baseline, Perioperative, up to 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Oct 2025
- Study start13 Jan 2026
- Primary completion15 Jan 2030 (estimated)
- Study completion15 Jan 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (8)Papers the sponsor has linked to this study.
- Other trials for Lung Cancer - Non Small CellStudies of the same condition, open and under way.
- More trials run by University of ArizonaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 48 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Arizona
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Stephanie Worrell, MD, Principal investigator, University of Arizona
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07216209
- Sponsor's protocol ID
- STUDY00005883
- Status last verified
- Apr 2026
- First submitted
- 10 Dec 2024
- Last updated
- 21 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: This is a local study and there are no plans to share individual patient data with outside researchers at this time.
Publications
Tan Z, Xue H, Sun Y, Zhang C, Song Y, Qi Y. The Role of Tumor Inflammatory Microenvironment in Lung Cancer. Front Pharmacol. 2021 May 17;12:688625. doi: 10.3389/fphar.2021.688625. eCollection 2021.
PubMed 34079469Ito M, Ishii G, Nagai K, Maeda R, Nakano Y, Ochiai A. Prognostic impact of cancer-associated stromal cells in patients with stage I lung adenocarcinoma. Chest. 2012 Jul;142(1):151-158. doi: 10.1378/chest.11-2458.
PubMed 22302300Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011.
PubMed 25428504Zhang L, Chen Y, Wang H, Xu Z, Wang Y, Li S, Liu J, Chen Y, Luo H, Wu L, Yang Y, Zhang H, Peng H. Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer. J Immunother Cancer. 2021 Jun;9(6):e002356. doi: 10.1136/jitc-2021-002356.
PubMed 34140315Rosero ID, Ramirez-Velez R, Lucia A, Martinez-Velilla N, Santos-Lozano A, Valenzuela PL, Morilla I, Izquierdo M. Systematic Review and Meta-Analysis of Randomized, Controlled Trials on Preoperative Physical Exercise Interventions in Patients with Non-Small-Cell Lung Cancer. Cancers (Basel). 2019 Jul 5;11(7):944. doi: 10.3390/cancers11070944.
PubMed 31284372Simpson RJ, Campbell JP, Gleeson M, Kruger K, Nieman DC, Pyne DB, Turner JE, Walsh NP. Can exercise affect immune function to increase susceptibility to infection? Exerc Immunol Rev. 2020;26:8-22.
PubMed 32139352Puchelle E, Zahm JM, Tournier JM, Coraux C. Airway epithelial repair, regeneration, and remodeling after injury in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006 Nov;3(8):726-33. doi: 10.1513/pats.200605-126SF.
PubMed 17065381Wang J, Linxweiler M, Yang W, Chan TA, Morris LGT. Immunomodulatory and immunotherapeutic implications of tobacco smoking in squamous cell carcinomas and normal airway epithelium. Oncotarget. 2019 Jun 11;10(39):3835-3839. doi: 10.18632/oncotarget.26982. eCollection 2019 Jun 11.
PubMed 31231463
Study at a glance
From the registry record, last updated by the sponsor on 21 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exercise and the Lung Cancer Tumor Microenvironment
- ClinicalTrials.gov ID
- NCT07216209
- Acronym / sponsor ID
- STUDY00005883
- Conditions
- Lung Cancer - Non Small Cell
- Keywords
- exercise, tumor microenvironment, lung cancer
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 48 participants (estimated)
- Lead sponsor
- University of ArizonaUniversity, hospital or other
- Study start
- 13 Jan 2026 (actual)
- Primary completion
- 15 Jan 2030 (estimated)
- Study completion
- 15 Jan 2030 (estimated)
- First posted
- 14 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
There is increased interest and knowledge about the lung cancer tumor microenvironment (TME). Investigators hypothesize that patients with better baseline physiologic health will have better post-operative outcomes and that strenuous exercise will alter the TME and genetic make-up of the tumor, improving the tumor immune response. Investigators aim to identify the peri-operative and clinical outcomes that differ based on pre-operative VO2max, HRV and resting heart rate following resection of early-stage lung cancer. The physiologic states that are individual and measurable with wearable devices include but are not limited to VO2max, heart rate variability (HRV), and average resting heart rate. Investgators hypothesize that a patient's pre-operative physiologic function with higher VO2max, HRV and lower resting heart rate will be associated with improved peri-operative and post-operative outcomes. Second, investigators will compare alterations in TME based on targeted pre-operative exercise (60-80% of their VO2 max for 75min/week x2 weeks) compared to normal activity adults following resection of early-stage lung cancer. Investigators hypothesize that strenuous exercise in the pre-operative period will impact the TME by increasing levels of cytokines.
Detailed description
Background
Lung cancer continues to be the most common cause of cancer related death in both men and women. Patients have variable responses to treatment, whether they receive neoadjuvant therapy or surgery alone. Many of these variations can be attributed to known patient risk factors including age, smoking status, and BMI. However, there are more complex pathophysiologic factors that affect how patients respond and recover from all insults, including cancer.
Lung cancer resides in a complex milieu known as the lung tumor microenvironment (TME). The TME includes the cellular makeup of the tumor as well as factors such as IL6, PDL1 ligand, COX2, PGE2, and other cytokines. These factors can cause the TME to change in states of inflammation, such as COPD, and impact carcinogenesis (1-3). Thus, it is reasonable to assume that other physiologic alterations can change the TME. These physiologic states may be alterable and could be used to improve the efficacy of targeted therapies.
The innate and adaptive immune cells in the lung TME harbor tumor promoting and suppressing activities, which may affect clinical outcomes. Cancer associated fibroblasts (CAF) isolated from human lung cancer tissues have been shown to secrete interleukin-6 (IL-6), which then stimulates Janus kinase 2(JAK2)-signal transducers. Through this mechanism, transcription 3 (STAT3) signaling is activated and ultimately leads to increased metastasis in vivo. CAFs modulate multiple immune pathways in the TME, as they also express PDL1 to blunt activation of T cells and cross present antigens to eliminate antigen-specific CD8+T cells via PDL2 and FASL. CAFs have been found to be indicators of poor prognosis, associated with nodal metastases and increased risk of recurrence (6).
Physical fitness and moderate intensity exercise training have been shown to improve immune responses to vaccination, reduce chronic low-grade inflammation, and improve various immune markers in several disease states including cancer, HIV, cardiovascular disease, diabetes, cognitive impairment, and obesity (4). In mouse models, exercise has been shown to decrease tumor incidence and growth by over 60% (5). Prior work by Simpson and colleagues have shown that even a single bout of aerobic exercise greatly increases NK cell and γδ T cell numbers as well as increases the proportion of total lymphocytes found in the peripheral blood. Exercise can also increase the number of cytotoxic T cells in the blood without increasing their proportion of total lymphocytes.
This study will capture the baseline physiologic state of patients with resectable lung cancer pre-operatively. The parameters captured will include but are not limited to: VO2max, heart rate variability (HRV), and average resting heart rate. Next, investigators will perform strenuous exercise on a subset of these patients and correlate this data with their TME and clinical peri-operative and post-operative outcomes. The TME will be evaluated with flow cytometry and real-time PCR after tumor resection and levels of IL1b, 4,6,11,12, TNFa, MCP1, TGFb, CD4 and 8 will be identified as well as the presence of PDL-1, EGFR mutations, ALK, ROS1, KRAS, BRAF.
In our clinical pilot data, strenuous exercise patients had important trends. Patients who self-reported strenuous exercise had better lung function, shorter time from diagnosis to surgery, more left sided tumors, shorter hospital LOS, and less prolonged air leaks. Long term outcomes are still pending regarding recurrence and overall survival.
Investigators hypothesize that patients with better baseline physiologic health will have better post-operative outcomes and that strenuous exercise will alter the TME and genetic make-up of the tumor, improving the tumor immune response to targeted therapies.
Specific Aims
Aim 1: Identify the peri-operative and clinical outcomes that differ based on pre-operative VO2max, HRV and resting heart rate following resection of early-stage lung cancer. The physiologic states that are individual and measurable with wearable devices include but are not limited to VO2max, heart rate variability (HRV), and average resting heart rate. Investigators hypothesize that a patient's pre-operative physiologic function with higher VO2max, HRV and lower resting heart rate will be associated with improved peri-operative and post-operative outcomes.
Aim 2: Compare alterations in TME based on targeted pre-operative exercise (60-80% of their VO2 max for 75min/week x2 weeks) compared to normal activity adults following resection of early-stage lung cancer. Investigators hypothesize that strenuous exercise in the pre-operative period will impact the TME by increasing levels of cytokines.
Significance
There is increased interest and knowledge about the lung cancer TME. There are data that demonstrate that alterations in the TME can occur based on inflammation. The literature also shows that increased level of CD8 and PDL1 expression are associated with better response to anti-PD-1 treatment (7). This occurs through the binding of PD-L1 to its receptors, which suppresses T-cell migration, proliferation and secretion of cytotoxic mediators and restricts tumor cell killing.. The PD-L1-PD-1 axis protects the host from overactive T-effector cells not only in cancer but also during microbial infections (8). If investigators can alter the level of cytokines and PD-LI expression with strenuous exercise, then patients: 1) may have improved operative outcomes, 2) could experience altered (improved) TME and may demonstrate improved response to targeted therapies.
Research Plan
Patients will be recruited from three busy thoracic surgery clinics, which see at least 30 lung cancer patients per month. All patients will be given a wearable device to record their physiologic data 24 hours/day for 2-3 weeks pre-operatively. This data will include VO2 max, HRV, resting heart rate and sleep score. The patients' peri-operative and post-operative outcomes will be recorded in a database and this data will then be linked to the patients' recorded physiologic data.
In addition to this baseline monitoring, all patients will be offered a lab exercise regimen. For completion of Aim 2, only three or four visits are necessary, amounting to approximately 4 hours of the patient's time. The initial visit will be for pre-exercise screening. If the patient is deemed healthy enough to participate, an exercise test to determine the ventilatory threshold of the participant will be conducted and the VO2 determined. In the subsequent visits, the patient will perform exercise for 30 minutes at 15% above the volunteer's ventilatory threshold. Ideally, the patients will be able to complete a minimum of three sessions prior to surgery. Those who are not able to participate due to interest or limitations in travel or physical limitations will serve as the control group.
Lung cancer specimens will be collected from all patients at the time of surgery. Investigators will perform flow cytometry and real-time PCR to identify levels of IL1b, 4,6,11,12, TNFa, MCP1, TGFb, CD4 and 8, and the presence of PDL-1, EGFR mutations, ALK, ROS1, KRAS, BRAF.
The next steps for this study will be to reproduce these experiments in a mouse model that has been previously performed by the collaborating lab. In this model investigators will be able to give targeted therapies, such as, PDL-1 inhibitors and measure the rate of response with and without strenuous exercise.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Exercise arm | Experimental | Behavioral: EXERCISE TRAINING WITH OR WITHOUT MEDICATIONAll patients will be offered a lab exercise regimen. For completion of Aim 2, only three or four visits are necessary, amounting to approximately 4 hours of the patient's time. The initial visit will be for pre-exercise screening. If the patient is deemed healthy enough to participate, an exercise test to determine the ventilatory threshold of the participant will be conducted and the VO2 determined. In the subsequent visits, the patient will perform exercise for 30 minutes at 15% above the volunteer's ventilatory threshold. Ideally, the patients will be able to complete a minimum of three sessions prior to surgery. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- lung cancer
- low risk for submaximal exercise testing in accordance with the risk stratification guidelines published by the American Heart Association and the American College of Sports Medicine (AHA/ACSM criteria).
Key exclusion criteria (15 listed)
- younger than 18 years of age
- select a condition on the ACSM-AHA pre-exercise screening questionnaire indicating that physician approval is required prior to exercise
- body mass index of >30 kg/m2
- waist girth of >102cm for men and >88cm for women
- have chronic/debilitating arthritis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EXERCISE TRAINING WITH OR WITHOUT MEDICATIONAll patients will be offered a lab exercise regimen. For completion of Aim 2, only three or four visits are necessary, amounting to approximately 4 hours of the patient's time. The initial visit will be for pre-exercise screening. If the patient is deemed healthy enough to participate, an exercise test to determine the ventilatory threshold of the participant will be conducted and the VO2 determined. In the subsequent visits, the patient will perform exercise for 30 minutes at 15% above the volunteer's ventilatory threshold. Ideally, the patients will be able to complete a minimum of three sessions prior to surgery. | Behavioural | Exercise arm |
Primary outcome
Tumor Microenvironment
Time frame: Baseline, Perioperative, up to 24 months
Lung cancer specimens will be collected from all patients at the time of surgery. Investigators will perform real-time PCR to identify levels of PDL-1
1 secondary outcome
Recurrence and Survival
Time frame: Baseline, Perioperative, up to 24 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Apr 2026.
- Background: PubMed 34079469Tan Z, Xue H, Sun Y, Zhang C, Song Y, Qi Y. The Role of Tumor Inflammatory Microenvironment in Lung Cancer. Front Pharmacol. 2021 May 17;12:688625. doi: 10.3389/fphar.2021.688625. eCollection 2021.
- Background: PubMed 22302300Ito M, Ishii G, Nagai K, Maeda R, Nakano Y, Ochiai A. Prognostic impact of cancer-associated stromal cells in patients with stage I lung adenocarcinoma. Chest. 2012 Jul;142(1):151-158. doi: 10.1378/chest.11-2458.
- Background: PubMed 25428504Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011.
- Background: PubMed 34140315Zhang L, Chen Y, Wang H, Xu Z, Wang Y, Li S, Liu J, Chen Y, Luo H, Wu L, Yang Y, Zhang H, Peng H. Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer. J Immunother Cancer. 2021 Jun;9(6):e002356. doi: 10.1136/jitc-2021-002356.
- Background: PubMed 31284372Rosero ID, Ramirez-Velez R, Lucia A, Martinez-Velilla N, Santos-Lozano A, Valenzuela PL, Morilla I, Izquierdo M. Systematic Review and Meta-Analysis of Randomized, Controlled Trials on Preoperative Physical Exercise Interventions in Patients with Non-Small-Cell Lung Cancer. Cancers (Basel). 2019 Jul 5;11(7):944. doi: 10.3390/cancers11070944.
- Background: PubMed 32139352Simpson RJ, Campbell JP, Gleeson M, Kruger K, Nieman DC, Pyne DB, Turner JE, Walsh NP. Can exercise affect immune function to increase susceptibility to infection? Exerc Immunol Rev. 2020;26:8-22.
- Background: PubMed 17065381Puchelle E, Zahm JM, Tournier JM, Coraux C. Airway epithelial repair, regeneration, and remodeling after injury in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006 Nov;3(8):726-33. doi: 10.1513/pats.200605-126SF.
- Background: PubMed 31231463Wang J, Linxweiler M, Yang W, Chan TA, Morris LGT. Immunomodulatory and immunotherapeutic implications of tobacco smoking in squamous cell carcinomas and normal airway epithelium. Oncotarget. 2019 Jun 11;10(39):3835-3839. doi: 10.18632/oncotarget.26982. eCollection 2019 Jun 11.
- Individual participant dataSharing planned: No. This is a local study and there are no plans to share individual patient data with outside researchers at this time.
Related trials for Lung Cancer - Non Small Cell
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Stephanie Worrell, MD principal investigator
University of Arizona
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing EXERCISE TRAINING WITH OR WITHOUT MEDICATION in people with Lung Cancer - Non Small Cell, run by University of Arizona at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Stephanie Worrell, MD (5206267806, sworrell@arizona.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Tumor Microenvironment (time frame: Baseline, Perioperative, up to 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07216209, which also lists 8 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Apr 2026.